All members of the Expert Panel complied with the Infectious Diseases Society of America (IDSA) policy on conflicts of interest, which requires disclosure of any financial or other interest that might be construed as constituting an actual, potential, or apparent conflict. Members of the Expert Panel were provided with the IDSA's conflict of interest disclosure statement and were asked to identify ties to companies developing products that might be affected by promulgation of the guidelines. Information was requested regarding employment, consultancies, stock ownership, honoraria, research funding, expert testimony, and membership on company advisory committees. The Expert Panel made decisions on a case-by-case basis as to whether an individual's role should be limited as a result of a conflict. Potential conflicts of interest are listed below.
P.G.P. has received honoraria and research grants and has served as a consultant to Schering-Plough, Astellas Pharma, Merck, Novartis, Basilea, and Pfizer Pharmaceuticals.
D.A. has served as an advisor and received honoraria from Pfizer Pharmaceuticals, Merck, and Astellas Pharma and has received research grants from Astellas Pharma, Pfizer Pharmaceuticals, and the National Institutes of Health.
D.K.B. has received research funding from Astellas Pharma, Biosynexus, Associates of Cape Cod, Pfizer, Rockeby, National Institute of Child Health and Human Development, and Thrasher Research Fund and has received organizational grants from AstraZeneca International, Johnson and Johnson, Medicines Company, MedImmune, and Pfizer.
T.C. has served as a consultant to Pfizer Pharmaceuticals, Merck, and Novartis and has received honoraria from Pfizer Pharmaceuticals, Merck, Novartis, Schering Plough, and Roche Diagnostics.
S.G.F. has received research grants from Pfizer, Amgen, and Merck; has received research funding from the National Institutes of Health and Columbia University; has served as a consultant for Theravance, Forest Pharmaceuticals, and Semorex; and holds stock in NovaDigm Therapeutics.
J.F.F. has received honoraria from Pfizer Pharmaceuticals, Merck, and Wyeth.
C.A.K. receives royalties from UpToDate and Springer Publisher and has received funding from Merck, the Centers for Disease Control and Prevention, Astellas Pharma, and Romark Laboratories.
B.-J.K. has served as a consultant or advisor to Basilea Pharmaceutica, Novartis, Pfizer Pharmaceuticals, and Schering-Plough and has received honoraria from MSD, Pfizer Pharmaceuticals, and Schering-Plough.
L.O.-Z. has served as a consultant for Astellas Pharma, Merck, Pfizer Pharmaceuticals, and Viracor; has received honoraria from Gilead, Merck, Pfizer, and Astellas Pharma; and has received research grants from Merck, Pfizer Pharmaceuticals, Astellas Pharma, Basilea Pharmaceutica, Associates of Cape Cod, and Viracor.
A.C.R. has served as a consultant or advisor for Pfizer Pharmaceuticals, Astellas Pharma, and Merck; has received honoraria from Pfizer Pharmaceuticals; and has received research grants from Pfizer Pharmaceuticals and Merck.
J.E.E. has received research funding from Schering-Plough, Schering, Enzon, Merck, Basilea Pharmaceutica, Pfizer Pharmaceuticals, Astellas Pharma, and Cubist Pharmaceuticals; has been on the scientific advisory boards of Merck, Pfizer, Gilead, Enzon, Cerexa, and Calixia; and is a founder of NovaDigm Therapeutics.
J.D.S. has received honoraria from Pfizer Pharmaceuticals, Merck, and KV Pharmaceuticals; has received research funding from Pfizer Pharmaceuticals, Merck, and Astellas Pharma; and has served as a consultant for Merck, Pfizer, and Embil.
T.J.W. has received research funding from Astellas Pharma and Vicuron through the Cooperative Research and Development Agreement.
J.F.R. is an employee of Astra Zeneca.